Physician profile
Rashmi Kumar
NPI 1396007068
$158,887.38
in general payments reported to CMS, 2019-2025
22 companies · $38K in 2025
The $38K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $84.33 · 2021: $80K · 2022: $622 · 2023: $602 · 2024: $39K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Food and Beverage: $6,013 · Travel and Lodging: $4,222 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,616.00 |
| Food and Beverage | $6,013.08 |
| Travel and Lodging | $4,222.42 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $83,956.90 | 2019-2025 | |
| Janssen Biotech, INC. | $71,011.83 | 2021-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $2,451.88 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $420.47 | 2022-2025 | Entyvio |
| Lilly USA, LLC | $251.94 | 2024-2025 | Omvoh |
| Celgene Corporation | $165.21 | 2022-2024 | Zeposia |
| Genzyme Corporation | $139.74 | 2022-2025 | |
| Celltrion USA INC. | $133.29 | 2024-2025 | Zymfentra, Vegzelma |
| Regeneron Healthcare Solutions, INC. | $51.01 | 2023 | Dupixent |
| Boston Scientific Corporation | $41.76 | 2019-2022 | |
| Braintree Laboratories, INC. | $34.51 | 2024-2025 | Sutab, Suflave |
| Fresenius Kabi USA, LLC | $32.09 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.14 | 2022 | |
| Merck Sharp & Dohme LLC | $27.39 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $21.43 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $19.91 | 2023 | Rebyota |
| Shionogi INC | $18.80 | 2019 | |
| Redhill Biopharma INC. | $18.05 | 2020 | |
| Ardelyx, INC. | $16.97 | 2023 | Ibsrela |
| Exact Sciences Corporation | $16.78 | 2023 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $14.85 | 2022 | |
| Allergan, INC. | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rashmi Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.